Zydus receives final approval from USFDA for Clobetasol Propionate Lotion
New Delhi: Zydus Cadila has received the final approval from the USFDA to market Clobetasol Propionate Lotion, (US RLD - Clobex Lotion), 0.05%.
Confirmation was recently made by the company via its release
This medication is used to treat a variety of skin conditions like eczema, psoriasis, dermatitis, allergies and rash. Clobetasol reduces the swelling, itching and redness that can occur in these types of conditions. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.
The group now has 272 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila group employs over 24,000 people worldwide and is dedicated to creating healthier communities globally.
Confirmation was recently made by the company via its release
This medication is used to treat a variety of skin conditions like eczema, psoriasis, dermatitis, allergies and rash. Clobetasol reduces the swelling, itching and redness that can occur in these types of conditions. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.
The group now has 272 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila group employs over 24,000 people worldwide and is dedicated to creating healthier communities globally.
Next Story
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd